about
Adjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care?3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial.Safety and efficacy of bevacizumab in combination with first-line chemotherapy in advanced breast cancer: data from the Italian cohort of the ATHENA trial.Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer.The intramuscular administration of granulocyte colony-stimulating factor as an adjunct to chemotherapy in pretreated ovarian cancer patients: an Italian Trials in Medical Oncology (ITMO) Group pilot study.The best treatment for older patients with breast cancer.The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned?ASCO 2009: What's New in Breast Cancer Therapy?Metabolomics: available results, current research projects in breast cancer, and future applications.Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002.Chemotherapy for metastatic breast cancer.Adjuvant therapy in elderly patients with breast cancer.Controversies in the adjuvant treatment of breast cancer: the role of taxanes.Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical OncologySelection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: where do we stand?Using specific cytotoxics with a targeted mind.Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology.New strategies to identify molecular markers predicting chemotherapy activity and toxicity in breast cancer.Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer.Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime?Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen.Adjuvant chemotherapy--the dark side of clinical trials. Have we learnt more?Quality indicators in breast cancer care.Chemotherapy with or without trastuzumab.The continued evidence from overviews: what is the clinical utility?HER2-positive metastatic breast cancer: a changing scenario.Challenges in the management of advanced, ER-positive, HER2-negative breast cancer.Continued value of adjuvant anthracyclines as treatment for early breast cancer.Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes.Oral single-agent chemotherapy in older patients with solid tumours: A position paper from the International Society of Geriatric Oncology (SIOG).De-escalating and escalating treatment beyond endocrine therapy in patients with luminal breast cancer.Controversial issues in the management of older adults with early breast cancer.Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients.Estimating the risk of chemotherapy toxicity in older patients with cancer: The role of the Vulnerable Elders Survey-13 (VES-13).Breast cancer in the elderly: which lessons have we learned?Adherence to oral cancer therapy in older adults: The International Society of Geriatric Oncology (SIOG) taskforce recommendations.Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study.
P50
Q27025860-2CCEFA96-D49C-4AC5-B9DE-BFFCA98BEB64Q30313649-BE645AC2-74CA-47C7-B03B-D4F0E84BFC29Q30317064-1102A6D5-1C57-4762-9856-6D30D72107C6Q30317067-867499A7-380B-4585-838E-CB788751BC99Q30317232-0C2F66CF-4931-45DA-944D-69FC40295EE6Q30858333-DF938170-F104-4061-A4FE-F121EE1B4E0BQ30923126-EAD91446-2924-4AF4-9899-D8369FA2DFBFQ33487862-233F9F78-1689-4F00-B412-0F5B34B03864Q33697318-DBD614D1-4BF1-42CA-89C1-3A9D9E2C157CQ33900916-0CC3ABB7-9403-464B-91F1-533AAF4E35BFQ34138399-7AFDEFAC-80E3-4AF0-A17A-66313577FB42Q34628323-A838349D-C53A-42D3-BE45-8CF24601FC97Q34803601-6000509C-4600-4A5C-AF87-BC52D4B51B31Q35764917-14D1327E-6068-4AFE-BD17-1D8BBC4F4284Q35873912-E4516734-467B-4A07-BE69-9693CC84F7D6Q35914681-E4BEB751-90D1-49E3-9DCF-3AE46D7BCDAAQ36080911-8205FFF2-9D8F-454C-9918-80679D398423Q36743070-59A543FA-7958-455C-981F-05BBDD8F27C7Q36919536-91FB405F-FD53-49D3-9071-C56FF3F31016Q37022459-96B4B43E-228C-48EC-AB02-34A9AE26A1DCQ37033624-E3D43427-B0D4-4F65-94E5-68FF8E095D41Q37208757-A9E2A3E4-97FC-469C-BDF6-B16CC29F6827Q37321208-B06F127D-2EFF-41E8-8C9C-1CB1364FFFF8Q37437264-008CFF6E-511E-41A5-A32E-C50CC4008103Q37633173-ECFD98AB-5F3C-4DCC-BE45-9635544CCC97Q37776924-E31DC499-B3F8-436F-9E6A-9CB415FD502BQ37799916-6938A3E1-C87E-41C6-B635-519E785C6C71Q38145845-C0B0D853-960F-4852-9541-3C39516EF5F0Q38369689-C0876199-7607-4254-B9E5-A9598FFD3A02Q38502890-235D8980-2BDA-477D-91B9-81FA686560D9Q38543409-34DB1613-A85D-4F3C-A4CD-802DB978A879Q38576669-BD309A00-AEB0-4480-9823-6095E8ED8266Q38580882-88226E90-CABC-4147-B8DC-3600A5B57898Q38694008-C9034A93-730D-4A2F-830C-C41A7BB14788Q38731511-C289A37A-3D6B-4222-8671-77C86F33DE3CQ38858924-0FD770F1-16F4-4001-84CD-CF55C44C9602Q38994164-BB1A5FB5-A49B-4A61-8977-378FAEDFCF36Q39303318-602D9F08-BD49-43C6-97D4-DECA98E79B06Q39333807-1140BB97-BC4B-4665-888E-4B6B84400523Q39632529-DBDCFAA0-26A8-419C-86D8-4D219D1C27F1
P50
description
researcher ORCID ID = 0000-0001-7989-8658
@en
name
L Biganzoli
@ast
L Biganzoli
@en
L Biganzoli
@nl
type
label
L Biganzoli
@ast
L Biganzoli
@en
L Biganzoli
@nl
prefLabel
L Biganzoli
@ast
L Biganzoli
@en
L Biganzoli
@nl
P31
P496
0000-0001-7989-8658